Wanqing Liu
Office Address
iBio Center Room 2401
Detroit, MI 48202
Department
Oncology, Pharmacology and Pharmaceutical Sciences
Research Interests
Cancer genetics and genomics; pharmacogenomics of anticancer drugs, precision medicine for cancer treatment.
Research Description
My primary research interest in cancer is to use integrated omics approach to understand the inter-individual difference in efficacy and toxicity of anti-cancer drugs and to develop precision strategies for cancer treatment and prevention.
- Pharmacogenomics of anti-cancer drugs: Our current research is focused on genome-wide characterization of the genetic and ontogenic determinants for drug metabolism enzyme and transporters in human livers, and to utilize these factors to build up better models to improve pharmacotherapy for cancer and other diseases in both adults and children.
- Genetic interaction between germline and somatic genome. We are interested in understanding the role of germline polymorphism in increasing susceptibility to somatic mutations in human cancers, and to understand how germline alleles regulating genome expression during the carcinogenesis. We are now using a stem-cell based model and omics based approach to address this question.
- Molecular markers for precision cancer treatment. We use omics-based strategy to identify molecular markers distinguishing patients with differential responses in both efficacy and toxicity to anti-cancer treatment. We are now interested in anti-cancer drug induced hepatotoxicity and biomarkers for immune therapy responses.
Recent Publications
Zheng G, Zhang Z, Liu H, Xiong Y, Luo L, Jia X, Peng C, Zhang Q, Li N, Gu X, Lu M, Song Y, Pan Y, Liu J, Liu W* and He Z*. HSP27-mediated Extracellular and Intracellular Signaling Pathways Synergistically Confer Chemo-Resistance in Squamous Cell Carcinoma of Tongue. Clin Cancer Res. 2018. Accepted.
Neumann E, Mehboob H, Ramirez R, Mirkov S, Liu W*. Age-dependent Hepatic UDP-glucuronosyltransferase Gene Expression and Activity in Children. Front Pharm. 2016; 7:437.
Wei R, DeVilbiss FT, Liu W. Genetic Polymorphism, Telomere Biology and Non-Small Lung Cancer Risk. J Genet Genomics. 2015;42:549-61.
Wei R, Cao L, Pu H, Wang H, Zheng Y, Niu X, Weng X, Zhang H, Favus M, Zhang L, Jia M, Zeng Y, Lu S, Wang H*, Liu Y*, Liu W*. TERT Polymorphism rs2736100-C Is Associated with EGFR Mutation-Positive Non-Small Cell Lung Cancer. Clin Cancer Res, 2015;21:5173-80.
Liu W, Ramírez J, Snezana Mirkov S, Chen P, Wu K, Gamazon ER, Sun C, Cox NJ, Cook ED, Das S, Ratain MJ. Genetic Factors Affecting Gene Transcription and Catalytic Activity of UDP-Glucuronyltransferases in Human Liver. Hum Mol Genet. 2014; 23:5558-69.
Kim J, Jones-Hall YL, Wei R, Myers J, Qi Y, Knipp GT, Liu W*. Association between hTERT rs2736100 polymorphism and sensitivity to anti-cancer agents. Front Genet. 2013;4:162.
Gamazon ER, Innocenti F, Wei R, Wang L, Zhang M, Mirkov S, Ramírez J, Huang RS, Cox NJ, Ratain MJ, Liu W*. A genome-wide integrative study of microRNAs in human liver. BMC Genomics. 2013;14:395.
Ramírez J, Kim TW, Liu W, Myers JL, Mirkov S, Owzar K, Watson D, Mulkey F, Gamazon ER, Stock W, Undevia S, Innocenti F, Ratain MJ. A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenet Genomics. 2014;24:129-32.
Wu K, House L, Liu W, Cho WC. Personalized targeted therapy for lung cancer. Int J Mol Sci. 2012;13:11471-96.
Young NR, Liu J, Pierce C, Wei TF, Grushko T, Olopade OI, Liu W, Shen C, Seiwert TY, Cohen EE. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Mol Oncol. 2012;S1574-7891:00121-4.
Education/Training
2002-2005 Research Associate, Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL
1996-2001 Ph.D. (Neurobiology/Psychiatric Genetics), Shanghai Institute of Physiology, Chinese Academy of Sciences, Shanghai, China
1992-1996 B.S. (Biological Sciences/Education), Shandong Normal University, Jinan, China